Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis

Blood

Volumn 124, Issue 15, 2014, Pages 2354-2361

  Petrich, Adam M ^a   Gandhi, Mitul ^a   Jovanovic, Borko ^a   Castillo, Jorge J ^b   Rajguru, Saurabh ^c   Yang, David T ^d   Shah, Khushboo A ^e   Whyman, Jeremy D ^e   Lansigan, Frederick ^e   Hernandez Ilizaliturri, Francisco J ^f   Lee, Lisa X ^g   Barta, Stefan K ^g   Melinamani, Shruthi ^h   Karmali, Reem ^h   Adeimy, Camille ⁱ   Smith, Scott ⁱ   Dalal, Neil ^j   Nabhan, Chadi ^k   Peace, David ^l   Vose, Julie ^m   Evens, Andrew M ⁿ   Shah, Namrata ^o   Fenske, Timothy S ^o   Zelenetz, Andrew D ^p   Landsburg, Daniel J ^q   Howlett, Christina ^r   Mato, Anthony ^s   Jaglal, Michael ^t   Chavez, Julio C ^t   Tsai, Judy P ^u   Reddy, Nishitha ^u   Li, Shaoying ^u   Handler, Caitlin ^v   Flowers, Christopher R ^v   Cohen, Jonathon B ^v,w   Blum, Kristie A ^w   Song, Kevin ^x   Sun, Haowei ^x   Press, Oliver ^y   Cassaday, Ryan ^y   Jaso, Jesse ^z   Medeiros, L Jeffrey ^z   Sohani, Aliyah R ^aa   Abramson, Jeremy S ^aa   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g ALBERT EINSTEIN CANCER CENTER   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁿ TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o MEDICAL COLLEGE OF WISCONSIN   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^r HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^s RUTGERS UNIVERSITY   (United States)

^t H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^u VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^v EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w OHIO STATE UNIVERSITY   (United States)

^x BRITISH COLUMBIA CANCER AGENCY   (Canada)

^y Fred Hutchinson Cancer Research Center   (United States)

^z UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^aa MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CONSOLIDATION CHEMOTHERAPY; DEATH; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOUBLE HIT LYMPHOMA; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOCYTOSIS; LOW RISK POPULATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT RESPONSE; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; REMISSION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907611124     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-578963     Document Type: Article

References (34)

1. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
2. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.
3. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25-33.
4. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(25):4135-4142.
5. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331.
6. Gandhi M, Petrich AM, Cassaday RD, et al. Impact of induction regimen and consolidative stem cell transplantation in patients with double hit lymphoma (DHL): a large multicenter retrospective analysis. ASH Annual Meeting, 2013; Abstract 640.
7. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-217.
8. Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ. "Double-Hit" cytogenetic status is not predicted by baseline clinicopathologic characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Hematol. 2014;166(3):369-374.
9. Petrich AMNC, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches [published online ahead of print July 24, 2014]. Cancer. doi:10.1002/cncr.28899.
10. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452-3459.
11. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36(4):612-619.
12. Abramson JS. Double hit lymphomas: evaluation of prognostic factors and impact of therapy. ASH Annual Meeting 2012;Abstract 1619.
13. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021-4031, quiz 4250.
14. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273-2279.
15. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891-901. 10.1111/bjh.12982 [Epub ahead of print].
16. Mead GM, Barrans SL, Qian W, et al. UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248-2260.
17. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915-1925.
18. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145-156.
19. Haowei S, Savage KJ, Karsan A, et al. Outcome of patients with double-hit lymphomas treated with CODOX-M/IVAC + R followed by hematopoietic stem cell transplantation in British Columbia. ASH Annual Meeting 2013;Abstract 1788.
20. Récher C, Coiffier B, Haioun C, et al; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858-1867.
21. Oki Y, Westin JR, Vega F, et al. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013;163(5):611-620.
22. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717-2724.
23. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013;369(18):1681-1690.
24. Klyuchnikov E, Bacher U, Kroll T, et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? Bone Marrow Transplant. 2014;49(1):1-7.
25. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: M.D. Anderson experience. ASH Annual Meeting 2013;Abstract 1776.
26. Howlett C, Goy A, Zielonka T, et al. Dose intensive induction followed by allogeneic stem cell transplantation more than doubles progression-free and overall survival in "double-hit" lymphoma (DHL). ASH Annual Meeting 2013;Abstract 2141.
27. Tsai J, Greer JP, Morgan DS, et al. Role of aggressive chemotherapeutic regimens in double hit lymphoma - can alternate aggressive induction regimens overcome the poor prognosis of diffuse large B cell lymphoma? ASH Annual Meeting 2013;Abstract 4361.
28. Cohen JB, Geyer SM, Lozanski G, et al. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677-1685.
29. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
30. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861.
31. ClinicalTrials.gov. Rituximab and combination chemotherapy in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00118209?term=calgb+50303&rank=1.
32. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842.
33. Gordon LI, Andersen J, Colgan J, et al. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Cancer. 1995;75(3):865-873.
34. Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012;119(20):4619-4624.